{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-128825","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2026-11-17T12:14:19+00:00","discovered_at":"2026-11-17T12:15:00.498367+00:00","generated_at":"2026-11-17T12:15:06.411420+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"SELLAS GPS hits Phase 3 REGAL primary endpoint: median OS 24.0 vs 14.7 months, HR 0.59 (p=0.035)","bullets":["Median overall survival 24.0 months for galinpepimut-S (GPS) vs 14.7 months for best available treatment; 41% reduction in risk of death (HR 0.59, two-sided p=0.035).","REGAL enrolled AML patients in second or later complete remission (CR2/CRp2+) after second-line or later salvage therapy who were ineligible for allogeneic stem cell transplant.","Topline analysis conducted at the pre-specified 80 death events per the trial's statistical analysis plan; treatment arms balanced on prognostic factors.","GPS generally well tolerated; treatment-related adverse events mostly grade 1/2 local injection site reactions, no new safety signals.","SELLAS plans an FDA meeting on an accelerated filing strategy and to advance BLA preparation for GPS in the first half of 2027; secondary endpoints pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-128825","json":"https://secwatch.observer/filing/0001104659-26-128825.json","markdown":"https://secwatch.observer/filing/0001104659-26-128825.md","text":"https://secwatch.observer/filing/0001104659-26-128825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926128825/0001104659-26-128825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926128825/tm2629947d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-17T12:15:06.411420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}